Dynavax Technologies Corporatio
10.30-0.16 (-1.53%)
Oct 29, 4:00:01 PM EDT · NasdaqGS · DVAX · USD
Key Stats
Market Cap
1.21BP/E (TTM)
-Basic EPS (TTM)
-0.45Dividend Yield
0%Recent Filings
8-K
Dynavax executive realignment
Dynavax Technologies reshuffled its executive team on October 15, 2025, transitioning David F. Novack from President and COO to Senior Vice President and COO effective January 1, 2026, amid an internal realignment of management roles. The company also removed Robert Janssen, M.D., as Chief Medical Officer and Senior VP of Clinical Development, Medical and Regulatory Affairs, effective upon hiring a successor or March 2, 2026, with his employment ending that date. Dynavax has launched a search for a new Chief Medical Officer. Leadership shifts like this reshape oversight.
8-K
Positive Z-1018 shingles trial results
Dynavax announced positive topline results from Part 1 of its Phase 1/2 trial for Z-1018, its novel shingles vaccine, on August 21, 2025, showing comparable immunogenicity to Shingrix in adults aged 50-69 while boasting a superior tolerability profile with just 12.5% grade 2/3 local reactions versus Shingrix's 52.6%. The company selected a 100 mcg gE dose with CpG 1018 and alum on an 8-week schedule for advancement. Part 2 in adults 70+ kicks off in 2H 2025. Z-1018 targets the $4.2B market but faces clinical trial risks.
8-K
Dynavax Q2 revenue surges 31%
Dynavax Technologies reported record Q2 2025 HEPLISAV-B net product revenue of $91.9 million, up 31% year-over-year, boosting total revenues to $95.4 million and GAAP net income to $18.7 million. The company refined its full-year HEPLISAV-B guidance to $315-325 million, signaling sustained U.S. market share gains to 45%. Pipeline advances include imminent top-line data from the shingles vaccine trial. Cash reserves stand at $613.7 million, yet expenses rose amid pipeline investments.
10-Q
Q2 FY2025 results
Dynavax posted solid Q2 momentum with total revenues of $95.4M, up 29% y/y from $73.8M, driven by HEPLISAV-B product sales surging 31% y/y to $91.9M on higher volumes and net pricing, while other revenue ticked down 1% y/y to $3.6M. Gross margin held steady at 85.2%, but operating income climbed to $14.4M from $5.2M y/y, reflecting controlled cost growth amid R&D investments in shingles and plague programs. Diluted EPS improved to $0.14 from $0.08 y/y, reconciling to 138.4M weighted shares with no anti-dilution flagged. Cash and equivalents stood at $99.1M with $514.6M in marketable securities, supporting $260.8M in convertible notes (2.00%-2.50% rates, maturities 2026-2030) after a March refinancing that incurred an $82.1M extinguishment loss, dragging YTD net to a $77.4M loss versus $2.7M profit last year. Free cash flow wasn't disclosed in the 10-Q. Yet competition from entrenched hepatitis B vaccines persists.
8-K
Board declassification approved
Dynavax Technologies stockholders approved declassifying the board on June 11, 2025, shifting to annual elections by 2028 via a phased approach, with the restated certificate filed on June 16. This move, backed by 94 million votes, aligns governance with modern standards while electing four Class I directors amid a proxy contest. Bylaws adjusted accordingly. Declassification enhances accountability.
IPO
Website
Employees
Sector
Industry
BVAXD
BioVaxys Technology Corp.
0.15-0.03
EBS
Emergent BioSolutions Inc.
9.40-0.07
GOVX
GeoVax Labs, Inc.
0.55-0.05
HLVX
HilleVax, Inc.
2.09+0.00
INO
Inovio Pharmaceuticals, Inc.
2.43-0.15
NNVC
NanoViricides, Inc.
1.86+0.33
NVAX
Novavax, Inc.
8.38-0.14
SNY
Sanofi
50.68-0.38
VALN
Valneva SE
9.12+0.00
ZYBT
Zhengye Biotechnology Holding L
2.46+0.28